High-flow Nasal Cannula therapy: A feasible treatment for vulnerable elderly COVID-19 patients in the wards

Approximately 80% of COVID-19 patients experience respiratory symptoms and roughly 20% of the patients develop severe symptoms requiring hospital admission.1 With the lack of effective antiviral drugs, symptomatic treatment with oxygen administration remains the cornerstone of the treatment. As an intermediate step between conventional oxygen administration and invasive mechanical ventilation, High-flow Nasal Cannula (HFNC) is widely used to treat hypoxemic respiratory failure. HFNC is a form of non-invasive ventilation and contains high flow, pre-heated and humidified air delivering high concentrations of oxygen.

Source: Heart and Lung - May 25, 2021 Category: Intensive Care Authors: Job van Steenkiste, Michael C. van Herwerden, Dolf Weller, Christiaan J. van den Bout, Rikje Ruiter, Jan G. den Hollander, Rachida el Moussaoui, Gert T. Verhoeven, Charlotte. van Noord, Marinus A. van den Dorpel Source Type: research